This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abe, J.-i. Articles by Berk, B. C. Search for Related Content PubMed PubMed Citation Articles by Abe, J.-i. Articles by Berk, B. C. Related Collections Contractile function Apoptosis Ischemic biology - basic studies

(Circulation Research. 2000;86:607.)
© 2000 American Heart Association, Inc.

Editorials

Role of Mitogen-Activated Protein Kinases in Ischemia and Reperfusion Injury

The Good and the Bad

Jun-ichi Abe, Christopher P. Baines, Bradford C. Berk

From the Center for Cardiovascular Research, University of Rochester, Rochester, NY.

Correspondence to Bradford C. Berk, MD, PhD, Cardiology Unit, Box 679, 601 Elmwood Ave, Rochester, NY 14642. E-mail Bradford_Berk@urmc.rochester.edu

Key Words: ischemia/reperfusion • mitogen-activated protein kinase • apoptosis • cardiomyocyte

	Introduction

 
There is growing evidence that multiple mitogen-activated protein (MAP) kinases are activated during ischemia and/or reperfusion and may contribute to the structural and functional changes after myocardial ischemia. A new study by Yue et al¹ in this issue of Circulation Research attempts to address the role of MAP kinases in ischemic myocardium and suggests that ERK1/ERK2 is part of a "survival" pathway whereas p38 and JNK mediate a "death" pathway in the ischemic myocardium.

Myocyte loss during the acute stage of myocardial infarction involves both apoptotic and necrotic cell death.^{2 3 4} Therefore, it is reasonable to think that the balance of cell survival and death is critical during the pathological evolution of postischemic cardiac dysfunction. Recently, many scientists seeking to elucidate the intricate relationship between signal transduction and this balance of survival and death in ischemic myocardium have focused on MAP kinases.

	MAP Kinases

 
MAP kinases are highly conserved serine/threonine kinases that are activated in response to a wide variety of stimuli including growth factors, G protein–coupled receptors, and environmental stresses.⁵ Consequently, they play a role in numerous cell functions including growth and proliferation. The MAP kinases themselves require dual phosphorylation on a Thr-X-Tyr motif to become active. Three major MAP kinase cascades have been extensively studied in the heart: extracellular signal–regulated kinases (ERK1 and ERK2), c-Jun N-terminal kinases (JNK1 and JNK2), and p38 kinases, of which the p38 and p38ß isoforms are found in the heart.⁵ Recently, a fourth MAP kinase member, big MAPK-1 (BMK1, also known as ERK5), has been identified . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Sato, D. S. Hutchinson, B. A. Evans, and R. J. Summers Mol. Pharmacol., November 1, 2008; 74(5): 1417 - 1428. [Abstract] [Full Text] [PDF]

				Y. C. Jin, K. J. Kim, Y. M. Kim, Y. M. Ha, H. J. Kim, U. J. Yun, K. H. Bae, Y. S. Kim, S. S. Kang, H. G. Seo, et al. Anti-Apoptotic Effect of Magnolol in Myocardial Ischemia and Reperfusion Injury Requires Extracellular Signal-Regulated Kinase1/2 Pathways in Rat In Vivo Experimental Biology and Medicine, October 1, 2008; 233(10): 1280 - 1288. [Abstract] [Full Text] [PDF]

				P. S. Wolf, H. E. Merry, A. S. Farivar, A. S. McCourtie, and M. S. Mulligan Stress-activated protein kinase inhibition to ameliorate lung ischemia reperfusion injury J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 656 - 665. [Abstract] [Full Text] [PDF]

				C. Morisco, C. Marrone, V. Trimarco, S. Crispo, M. G. Monti, J. Sadoshima, and B. Trimarco Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression Cardiovasc Res, December 1, 2007; 76(3): 453 - 464. [Abstract] [Full Text] [PDF]

				J. A. Wall, J. Wei, M. Ly, P. Belmont, J. J. Martindale, D. Tran, J. Sun, W. J. Chen, W. Yu, P. Oeller, et al. Alterations in oxidative phosphorylation complex proteins in the hearts of transgenic mice that overexpress the p38 MAP kinase activator, MAP kinase kinase 6 Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2462 - H2472. [Abstract] [Full Text] [PDF]

				N. C. Weber, J. Stursberg, N. M. Wirthle, O. Toma, W. Schlack, and B. Preckel Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo Br. J. Anaesth., September 1, 2006; 97(3): 298 - 306. [Abstract] [Full Text] [PDF]

				D. K. Das and N. Maulik Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., February 1, 2006; 6(1): 36 - 47. [Abstract] [Full Text] [PDF]

				H.-F. Su, A. Samsamshariat, J. Fu, Y.-X. Shan, Y.-H. Chen, D. Piomelli, and P. H. Wang Oleylethanolamide Activates Ras-Erk Pathway and Improves Myocardial Function in Doxorubicin-Induced Heart Failure Endocrinology, February 1, 2006; 147(2): 827 - 834. [Abstract] [Full Text] [PDF]

				T. Okada, H. Otani, Y. Wu, S. Kyoi, C. Enoki, H. Fujiwara, T. Sumida, R. Hattori, and H. Imamura Role of F-actin organization in p38 MAP kinase-mediated apoptosis and necrosis in neonatal rat cardiomyocytes subjected to simulated ischemia and reoxygenation Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2310 - H2318. [Abstract] [Full Text] [PDF]

				T. Sumida, H. Otani, S. Kyoi, T. Okada, H. Fujiwara, Y. Nakao, M. Kido, and H. Imamura Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580 Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2726 - H2734. [Abstract] [Full Text] [PDF]

				J. J. Martindale, J. A. Wall, D. M. Martinez-Longoria, P. Aryal, H. A. Rockman, Y. Guo, R. Bolli, and C. C. Glembotski Overexpression of Mitogen-activated Protein Kinase Kinase 6 in the Heart Improves Functional Recovery from Ischemia in Vitro and Protects against Myocardial Infarction in Vivo J. Biol. Chem., January 7, 2005; 280(1): 669 - 676. [Abstract] [Full Text] [PDF]

				D.-G. Cho, M. R. Mulloy, P. A. Chang, M. D. Johnson, A. S. Aharon, T. A. Robison, T. L. Buckles, D. W. Byrne, and D. C. Drinkwater Jr Blockade of the extracellular signal-regulated kinase pathway by U0126 attenuates neuronal damage following circulatory arrest J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1033 - 1040. [Abstract] [Full Text] [PDF]

				T. Force, K. Kuida, M. Namchuk, K. Parang, and J. M. Kyriakis Inhibitors of Protein Kinase Signaling Pathways: Emerging Therapies for Cardiovascular Disease Circulation, March 16, 2004; 109(10): 1196 - 1205. [Abstract] [Full Text] [PDF]

				Y. Chen, R. Rajashree, Q. Liu, and P. Hofmann Acute p38 MAPK activation decreases force development in ventricular myocytes Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2578 - H2586. [Abstract] [Full Text] [PDF]

				D. G. Souza, R. Guabiraba, V. Pinho, A. Bristow, S. Poole, and M. M. Teixeira IL-1-Driven Endogenous IL-10 Production Protects Against the Systemic and Local Acute Inflammatory Response Following Intestinal Reperfusion Injury J. Immunol., May 1, 2003; 170(9): 4759 - 4766. [Abstract] [Full Text] [PDF]

				S. E. Regan, M. Broad, A. M. Byford, A. R. Lankford, R. J. Cerniway, M. W. Mayo, and G. P. Matherne A1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H859 - H866. [Abstract] [Full Text] [PDF]

				J. Pye, F. Ardeshirpour, A. McCain, D. A. Bellinger, E. Merricks, J. Adams, P. J. Elliott, C. Pien, T. H. Fischer, A. S. Baldwin Jr., et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H919 - H926. [Abstract] [Full Text] [PDF]

				H. Ogita, K. Node, H. Asanuma, S. Sanada, Y. Liao, S. Takashima, M. Asakura, H. Mori, Y. Shinozaki, M. Hori, et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart J. Am. Coll. Cardiol., September 4, 2002; 40(5): 998 - 1005. [Abstract] [Full Text] [PDF]

				Y. Takeishi, Q. Huang, J.-i. Abe, W. Che, J.-D. Lee, H. Kawakatsu, B. D Hoit, Bradford.C Berk, and R. A Walsh Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy Cardiovasc Res, January 1, 2002; 53(1): 131 - 137. [Abstract] [Full Text] [PDF]

				R. Hattori, H. Otani, T. Uchiyama, H. Imamura, J. Cui, N. Maulik, G. A. Cordis, L. Zhu, and D. K. Das Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1066 - H1074. [Abstract] [Full Text] [PDF]

				J. L. Martin, M. Avkiran, R. A. Quinlan, P. Cohen, and M. S. Marber Antiischemic Effects of SB203580 Are Mediated Through the Inhibition of p38{alpha} Mitogen-Activated Protein Kinase: Evidence From Ectopic Expression of an Inhibition-Resistant Kinase Circ. Res., October 26, 2001; 89(9): 750 - 752. [Abstract] [Full Text] [PDF]